BriaCell Therapeutics Corp.’s Post

Clinical benefit in the Bria-IMT™ Phase 1/2 study was seen in 55% of evaluable patients across all subtypes of #breastcancer as shown in Figure 2 below. Learn more: https://bit.ly/3KsI9hV #ASCO24 #metastaticbreastcancer

The clinical data BriaCell presented at #ASCO24 shows that Bria-IMT™ offers extended progression-free survival and clinical benefit in heavily pre-treated, ADC resistant #breastcancer patients versus those in other similar studies. Learn more: https://bit.ly/3KsI9hV #metastaticbreastcancer

Clinical trials progress through 4 phases that have different numbers of participants and different goals, like testing basic treatment safety and comparing a new treatment to the standard of care. Learn more: https://lnkd.in/ehP36AxW #clinicaltrialawareness #colorectalcancer #coloncancer #rectalcancer #clinicaltrials #fastfacts

💫 #ONCOnews 💫 🌟 Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS 👉 RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) 🔗 https://buff.ly/3yhibvg #OncEd #OncoAlert

In our latest published study, #TissueCypher results for 8,080 #BarrettsEsophagus patients (from tests ordered by 891 physicians at 505 clinical sites) found high risk patients in all clinicopathologic subsets. Patients identified by TissueCypher high-risk scores had a personal risk of progression 2X higher than confirmed low-grade dysplasia. Check out our clinical summary of the data: https://lnkd.in/eN2zaYmq

Patient for Life is a program that Ambry offers at no cost for certain tests. When new gene-disease associations are validated, updated reports are provided proactively to affected patients, which has resulted in answers for an additional 5% of patients. Learn more: https://hubs.ly/Q02zSg1c0

Living with Glanzmann Thrombasthenia (GT) means navigating frequent and often severe bleeding events. Recent findings from the Glanzmann’s 360 study reveal the most common bleed sites among men, women, and children. Women are especially impacted, with 92% reporting heavy or prolonged menstrual periods. Of those who completed an online questionnaire, 59% described blood loss in their most recent period as “heavy” or “very heavy.” Explore valuable resources for women and bleeding disorders, including short informational videos, at https://lnkd.in/esf-DB6k At Hemab, we are advancing the first prophylactic treatment for GT to reimagine the standard of care so patients can live better lives. We are currently enrolling participants in a Phase 2 clinical trial for HMB-001, an investigational subcutaneous injection designed to restore healthy clot formation and prevent the number and severity of bleeding events. Read more in the Haemnet GT 360 study and stay tuned for more findings: https://lnkd.in/eNumsur4

📰 The #CardioNerds Academy Fellows Drs. Anna Radakrishnan, MD, MBA and Georgia Vasilakis Tsatiris conclude a 3-part discussion with Dr. Kevin Alexander by exploring the findings of the ATTRibute-CM clinical trial, which found that #acoramidis treatment resulted in an early and profound reduction in #cardiovascular hospitalizations and mortality in patients with ATTR-CM. 💻 Watch More: https://buff.ly/3KGaFwq

Our recent study demonstrated that the combination of LIVERSTAT and Fibroscan offers a powerful one-step assessment for MASLD-related fibrosis. This combination: ✅ Identifies twice as many advanced fibrosis (F3F4) cases compared to the traditional FIB-4 and Fibroscan combo. ✅ Eliminates the "grey zone" in detection, ensuring no F3F4 patients are missed.
 ✅ Detects 41% of F3F4 cases missed by FIB-4. This streamlined approach offers a more accurate and efficient tool for early fibrosis identification, helping to ensure timely intervention and improved patient outcomes. Find out more about the study: https://zurl.co/9MQQ #MASLD #LIVERSTAT #Fibroscan #AdvancedFibrosis #LiverHealth #MASH

Breast Cancer-Related Lymphedema (BCRL) can be reversed if detected early. Studies from the University of Kansas show that stages 0 and 1 are reversible, while stages 2 and 3 are not. Early intervention and monitoring with Bioimpedance Spectroscopy (BIS) can significantly reduce BCRL rates. Discover how our Lymphedema Prevention Program (LPP) supports early detection and improves patient outcomes. Learn More 🔗https://ow.ly/tonJ50TfBJT. #BCRL #EarlyDetection #LymphedemaPrevention #BreastCancerCare"